MannKind Corporation (NASDAQ:MNKD) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
On February 26, 2019, MannKind Corporation issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
Exhibit 99.1. Press release dated February 26, 2019
MANNKIND CORP Exhibit
EX-99.1 2 mnkd-ex991_6.htm EX-99.1 mnkd-ex991_6.htm EXHIBIT 99.1 MannKind Corporation Fourth Quarter and Year-End 2018 Earnings Call Conference Call to Begin Today at 9:00 AM ET • 4Q 2018 Total Revenues were $16.0 million; 254% growth vs. 4Q 2017 o 4Q 2018 Afrezza Net Revenue was $5.7 million; 28% growth vs. 4Q 2017 on a GAAP basis and 86% when adjusted for a one-time change in estimate recognized in 4Q 2017 o 4Q 2018 Collaborations and Services Revenue was $10.3 million • 2018 Total Revenues were $27.9 million; 137% growth vs. 2017 o 2018 Afrezza Net Revenue was $17.3 million; 88% growth vs. 2017 o 2018 Collaborations and Services Revenue was $10.6 million • Ended 2018 with $71.7 million in cash,…
To view the full exhibit click here
About MannKind Corporation (NASDAQ:MNKD)
MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company’s fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.
